文献速递新发突发、热带与寄生虫病

吡咯萘啶-青蒿琥酯在越南青蒿素耐药区治疗无并发症恶性疟的疗效与安全性

Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018).
PubMed 文献 · Clin Infect Dis · 2020-01-01

该前瞻性、开放标签、单臂观察性临床试验于2017年5月至2018年12月在越南5省开展,评估口服吡咯萘啶-青蒿琥酯每日一次连续3天治疗成人及儿童镜检确诊恶性疟的安全性及疗效。主要结局为第42天PCR校正的充分临床和寄生虫学应答(ACPR),累积发生率为96.1%(95%CI 91.4-98.2)。结论认为该方案可用于越南青蒿素耐药区以多样化抗疟治疗。

要点

  • 第42天PCR校正ACPR累积发生率为96.1%(95%CI 91.4-98.2)。
  • 第3天寄生虫血症比例为24.0%(95%CI 17.7-31.2)。
  • 多数青蒿素耐药分离株同时具有plasmepsin2拷贝数增加(75.9%)。

核心结论

  • 吡咯萘啶-青蒿琥酯可用于越南青蒿素耐药恶性疟地区以多样化抗疟治疗。

研究设计与样本

  • 前瞻性、开放标签、单臂观察性临床试验,2017年5月至2018年12月在越南Binh Phuoc、Dak Nong、Gia Lai、Khanh Hoa和Ninh Thuan五省开展。
  • 纳入镜检确诊恶性疟的成人和儿童,口服吡咯萘啶-青蒿琥酯每日一次连续3天,第0-3天住院,第7、14、21、28、35、42天随访。

主要发现

  • 第42天PCR校正ACPR累积发生率为96.1%(95%CI 91.4-98.2;Kaplan-Meier法)。
  • 符合方案分析中第42天PCR校正ACPR比例为96.1%(147/153;95%CI 91.7-98.5)。
  • 第3天寄生虫血症比例为24.0%(40/167;95%CI 17.7-31.2)。
  • Kelch13(C580Y)突变流行率:Binh Phuoc 97.7%(43/44)、Dak Nong 96.2%(25/26)、Gia Lai 57.8%(37/64)、Khanh Hoa 66.6%(6/9)、Ninh Thuan 3.6%(1/28)。
  • 多数青蒿素耐药分离株同时有plasmepsin2拷贝数增加(75.9%;85/112),1株(Binh Phuoc)同时有Kelch13(C580Y)及plasmepsin2和Pfmdr1拷贝数增加。

临床怎么用

  • 在越南青蒿素耐药恶性疟地区,可考虑使用吡咯萘啶-青蒿琥酯作为多样化抗疟治疗方案之一。
  • 治疗期间第7天可见无症状性转氨酶短暂升高,至第28天消退,需注意监测肝功能。

局限性

  • 本研究为单臂观察性临床试验,无平行对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant Plasmodium falciparum undermines the efficacy of currently deployed antimalarial therapies in southern Viet Nam. METHODS: Between May 2017 and December 2018, this prospective, open-label, single-arm, observational clinical trial, conducted in Binh Phuoc, Dak Nong, Gia Lai, Khanh Hoa, and Ninh Thuan provinces, evaluated the safety and efficacy of oral pyronaridine-artesunate once daily for 3 consecutive days in adults and children with microscopically confirmed P. falciparum malaria. Patients were treated as inpatients for Days 0-3, with follow-up visits on Days 7, 14, 21, 28, 35, and 42. The primary outcome was the proportion of polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 42. RESULTS: The cumulative incidence of PCR-adjusted ACPR at Day 42 was 96.1% (95% confidence interval [CI] 91.4-98.2; Kaplan-Meier). In the per-protocol analysis, the proportion of patients with Day 42 PCR-adjusted ACPR was 96.1% (147/153; 95% CI 91.7-98.5). The proportion of patients with parasitemia at Day 3 was 24.0% (40/167; 95% CI 17.7-31.2). The prevalences of the Kelch13 (C580Y) mutation were: in Binh Phuoc, 97.7% (43/44); in Dak Nong, 96.2% (25/26); in Gia Lai, 57.8% (37/64); in Khanh Hoa, 66.6% (6/9); and in Ninh Thuan, 3.6% (1/28). The majority of artemisinin-resistant isolates also had increased plasmepsin2 copy number (75.9%; 85/112). There was 1 isolate (Binh Phuoc) that had Kelch13 (C580Y) plus increased plasmepsin2 and Pfmdr1 copy numbers. Asymptomatic transient increases in alanine transaminase and aspartate transaminase were observed at Day 7, resolving by Day 28. CONCLUSIONS: Pyronaridine-artesunate can be used to diversify antimalarial therapy in areas of artemisinin-resistant P. falciparum in Viet Nam. CLINICAL TRIALS REGISTRATION: ACTRN12618001274268.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Quang Bui P, Hong Huynh Q, Thanh Tran D, et al. Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018). Clin Infect Dis. 2020. PMID: 31251812. doi:10.1093/cid/ciz580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。